PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
PhaseBio Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 5, 2019
PhaseBio Pharmaceuticals reported fiscal year 2018 executive compensation information on April 5, 2019.
In 2018, four executives at PhaseBio Pharmaceuticals received on average a compensation package of $507K, a 29% increase compared to previous year.
Average pay of disclosed executives at PhaseBio Pharmaceuticals
Jonathan P. Mow, Chief Executive Officer, received $596K in total, which increased by 37% compared to 2017. 60% of Mow's compensation, or $359K, was in salary. Mow also received $201K in non-equity incentive plan, $35K in option awards, as well as $828 in other compensation.
John Lee, Chief Medical Officer, received a compensation package of $501K, which increased by 35% compared to previous year. 65% of the compensation package, or $326K, was in salary.
John Sharp, Chief Financial Officer, earned $465K in 2018, a 26% increase compared to previous year.
John P. Sharp, Chief Financial Officer, received $465K in 2018.
Related executives
You may also like
Source: SEC filing on April 5, 2019.